On July 29, 2024, the U.S. FDA approved Alpha Cognition Inc.'s ALPHA-1062 (Zunveyl ®), an Acetylcholinesterase (AChE) inhibitor, for treating mild-to-moderate Alzheimer’s disease. This condition ...
A patent from Centre National de la Recherche Scientifique (CNRS), McGill University and Sorbonne University discloses new acetylcholinesterase (AChE) inhibitors reported to be useful for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results